Clinical trials: Digestive Organs--Cancer
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Rectal Cancer, Organ Preservation
Treatment Strategy for Rectal Cancer Patients With Complete Clinical Response
This was a propensity-score matched observational analysis, comparing the oncological outcome of surgical resection vs watch and wait apporach for rectal cancer patients with a cCR.
- Trial name
- NCT03846726
- Testing
- standard TME surgery
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Yuan-hong Gao
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Colon Cancer
Colon Cancer Prognosis After Radical Surgery
1. Radical surgery. It is supposed to improve prognosis of colon cancer. A surrogate measure of achievement of radical surgery is the number of lymph nodes removed with the specimen. 2. Markers.
- Trial name
- NCT00963352
- Where
- 2 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Haraldsplass Deaconess Hospital
Colorectal Neoplasm, Liver Neoplasm
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan.
- Conditions
- Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00001576
- Testing
- Melphalan, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Cancer, Pancreatic Ductal Cancer
The Natural History of Solid Organ Cancer Stem Cells (SOCSC)
Background: Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis).
- Conditions
- Hepatic Cancer, Pancreatic Ductal Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT00923052
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- National Cancer Institute (NCI)
Malignancy, Transplant Complication
Epidemiology of Complications After Solid Organ Transplantation - EpCOT Study
Cancer remains a major cause of morbidity and mortality post solid organ transplantation. While mortality from the other leading causes of death post-transplantation (e.g.
- Conditions
- Malignancy, Transplant Complication, Cancer, Kidney Failure
- Trial name
- EpCOT (NCT02991105)
- Where
- 2 sites in United Kingdom
- Volunteers
- 85,410 people
- Sponsor
- University of Birmingham
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University
Gastric Cancer, Sentinel Lymph Node
Gastric Cancer Sentinel Lymph Node Mapping
Gastric cancer has an incidence in North America of over 24,000 new cases annually, of which approximately 15% are diagnosed at an early stage.
- Conditions
- Gastric Cancer, Sentinel Lymph Node, Early Gastric Cancer
- Trial name
- NCT03049345
- Testing
- Sentinel Lymph Node Sampling, Radioactive Tracers, Methylene Blue 20 MG/ML
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Cervical Cancer
Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination
A research project is currently being undertaken looking at Human Papilloma Virus (HPV) vaccination in special risk groups. It aims to see if young women with a chronic illness respond well to the HPV vaccine or whether they may…
- Trial name
- HPV (NCT00964210)
- Testing
- Licensed quadrivalent HPV vaccine, Gardasil
- Where
- Australia
- Volunteers
- 240 people
- Sponsor
- Murdoch Childrens Research Institute
Liver Neoplasms, Neoplasm Metastasis
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan.
- Trial name
- NCT00001587
- Testing
- Isolated hepatic portal and arterial perfusion, Melphalan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Liver Diseases, Liver Cancer
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation.
- Conditions
- Liver Diseases, Liver Cancer, Liver Cirrhosis, Liver Failure
- Trial name
- NCT07053488
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Heart Cancer, Kidney Cancer
Cancer Development In Organ Transplant Recipients
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis.
- Conditions
- Heart Cancer, Kidney Cancer, Lung Cancer, Pancreas Cancer
- Trial name
- NCT02333279
- Where
- Switzerland
- Volunteers
- 1,800 people
- Sponsor
- University of Zurich